Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Joel Lahn

Nephrology Owings Mills, MD Medical Doctor

NPI 1538167960 CMS profile 296598

25 Crossroads Dr, Suite 205, Owings Mills, MD 21117

Open in the dashboard

General payments

$604

14 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Joel Lahn of Owings Mills, MD is reported in the CMS Open Payments database as having received $604 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $101 1
2020 General $85 5
2019 General $419 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joel Lahn
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Joel Lahn were reported at $0. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Joel Lahn Nephrology median Middle half National median
2019 $419 $236 $90–$588 $163
2020 $85 $135 $46–$364 $114
2021 $0 $202 $67–$551 $132
2022 $0 $242 $77–$695 $149
2023 $101 $254 $84–$766 $160
2024 $0 $300 $99–$852 $164
2025 $0 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $265 3 payments
  2. Calliditas Therapeutics US Inc. $101 1 payment
  3. Amgen Inc. $96 1 payment
  4. Janssen Pharmaceuticals, Inc $60 4 payments
  5. Allergan Inc. $26 1 payment
  6. Baxter Healthcare $17 1 payment
  7. Pfizer Inc. $16 1 payment
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13 1 payment
  9. E.R. Squibb & Sons, L.L.C. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $604 14 payments
Products named General payments · program years 2019–2023
  1. LOKELMA $265 3 payments
  2. TARPEYO $101 1 payment
  3. Parsabiv $96 1 payment
  4. XARELTO $60 4 payments
  5. TEFLARO $26 1 payment
  6. Renal - PD $17 1 payment
  7. ELIQUIS Cardiovascular;Metabolic Disease $16 1 payment
  8. VYNDAQEL $16 1 payment
  9. LifeVest $13 1 payment
  10. ELIQUIS Cardiovascular $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record